Chat with us

Fexofenadine Montelukast Indian Exporter to USA | Pharmacy Sourcing Washington | Ernest Impex

Technical & Clinical Profile: Algreta M 120 mg Tablets

Optimizing the cross-border distribution of combination respiratory therapies requires an uncompromised commitment to quality and supply stability. Ernest Impex coordinates seamless, temperature-protected shipping channels directly from certified Indian production environments to target markets worldwide.

1. Active Ingredient Composition & Dual-Action Archetype

Algreta M 120 mg presents a highly effective, dual-action mechanism by pairing an advanced second-generation antihistamine with a targeted leukotriene modifier:

Fexofenadine Hydrochloride (120 mg): A highly selective peripheral receptor antagonist. It successfully interrupts systemic histamine cascades without causing the heavy central nervous system drowsiness commonly associated with older generation antihistamines.
Montelukast Sodium (equivalent to Montelukast 10 mg): A potent, selective cysteinyl leukotriene receptor antagonist. It works directly within respiratory tissues to prevent leukotriene-mediated inflammation, airway constriction, and mucus accumulation.

2. Primary Clinical Indications & Target Therapeutic Scope

Algreta M 120 mg tablets are prescribed globally within pulmonology, immunology, and ENT clinics to treat the following:

Allergic Rhinitis (Seasonal & Perennial): Relieves persistent sneezing, rhinorrhea (runny nose), nasal itching, congestion, and watery eyes triggered by pollen, animal dander, mold, or dust mites.
Comorbid Asthma & Allergic Rhinitis: Offers daily prophylactic control for patients who experience upper airway allergy symptoms alongside chronic bronchospasms or exercise-induced asthma.
Chronic Idiopathic Urticaria: Alleviates itching, hives, and localized tissue swelling in stubborn skin-based allergic reactions.

Mechanism of Action & Systemic Pharmacokinetics

Histamine Blockade: Fexofenadine actively blocks the interaction of histamine with peripheral receptors on effector cells, subduing capillary permeability and sensory nerve stimulation in nasal passages.

Leukotriene Inhibition: Montelukast precisely binds to the receptor, stopping the action of inflammatory leukotrienes excreted by mast cells and eosinophils. This reduces mucosal edema and clears breathing passages.

Pharmacokinetic Action: Following oral intake, both components absorb efficiently. Fexofenadine reaches peak plasma concentration in roughly 1 to 3 hours and does not cross the blood-brain barrier. Montelukast is rapidly absorbed with a mean oral bioavailability of 64% and is extensively processed via hepatic cytochrome enzymes, primarily CYP3A4, 2C8, and 2C9. The systemic effect provides a reliable, continuous therapeutic window over a 24-hour cycle, supporting a simple once-daily dosing protocol.

⚠️ Side Effects & Safety Profile

Common Neurological & Systemic Reactions: Mild headaches, dizziness, dry mouth, generalized fatigue, and occasional low-level drowsiness or reduced concentration.

Gastrointestinal Disturbances: Transient nausea, dyspepsia, abdominal pain, diarrhea, or episodes of vomiting.

Upper Respiratory & Immune System Alert: Mild pharyngitis, cough, influenza-like systemic symptoms, or transient elevations in serum transaminases (ALT/AST).

Neuropsychiatric Warnings (Montelukast Component):

Patients, families, and healthcare groups must monitor for unexpected neuropsychiatric changes. While uncommon, symptoms may include sleep disturbances, vivid dreams, anxiety, agitation, aggression, depression, or suicidal ideation. If these behaviors manifest, immediate cessation and professional psychiatric review are mandatory.

Hypersensitivity & Contraindications:

Discontinue immediately if signs of systemic eosinophilia or vasculitis matching Churg-Strauss syndrome appear. Avoid concurrent consumption of alcohol, as it can worsen drowsiness. Do not take within 30 minutes of administering aluminum- or magnesium-based antacids, as they significantly decrease fexofenadine absorption

📦 Regulatory Documentation & Storage Framework

Temperature Ranges: Store bulk blister cartons in cool, dark environments below 30°C (86°F). Avoid exposure to extreme heat profiles.

Moisture & Fruit Juice Protections: Retain the solid tablets within their original Alu-PVC packaging matrix until clinical dispensing. Store in spaces maintaining relative humidity levels below 60%. Patients should be advised never to ingest this medication with fruit juices (grapefruit, orange, or apple), as they can impair the biological absorption and clinical efficacy of fexofenadine.

Customs-Ready Export Documentation Packets

Official Certificate of Analysis (COA): Certifies active ingredient assay uniformity, precise compound dissolution kinetics, and freedom from trace impurities.

Comprehensive Batch Production Records: Verifies exact manufacturing tracking lines, regulatory compliance tags, and validated shelf-life dates.

Compliant International Trade Invoices: Providing verified packing manifests, certified country-of-origin listings, and explicit international airway bills designed for sensitive pharmaceuticals.

PRESCRIPTION MEDICINE IS : YES

Clinical Disclaimer : This document is prepared strictly for wholesale procurement groups, and high-authority digital indexing profiles. Algreta M 120 mg is a dual-action prescription-only medication (PRESCRIPTION MEDICINE IS YES). It must be distributed and dispensed exclusively upon the presentation of a valid prescription from a licensed healthcare practitioner. It is strictly contraindicated in individuals with known hypersensitivity to fexofenadine, montelukast, or any core excipients, and should be used with extreme caution in patients with underlying severe renal or hepatic impairment.